Navidea biopharmaceuticals announces new senior regulatory consultant and return of former director of regulatory affairs

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today welcomed kenneth berger, ph.d., as senior regulatory consultant, and the return of the company's former director of regulatory affairs, richard mcferron. navidea's former chief regulatory officer, dr. michel mikhail, is no longer with the company. dr. berger brings decades of ex
NAVB Ratings Summary
NAVB Quant Ranking